Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq.
Open accessPreprint — published as 10.22578/ijms.19.1.14 · Paper page
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Objectives: COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Methods: Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2-3 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters. Results: among all patients and among severe patients, 3/70 (4.28%) and 1/11 (9%), respectively progressed to a more advanced stage of the disease in the Ivermectin-Doxycycline group versus 7/70 (10%) and 7/22 (31.81%), respectively in the control group (P>0.05). The mortality rate was 0/48 (0%), 0/11 (0%), and 2/11 (18.2%) in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 0/48 (0%), and 6/22 (27.27%) in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (p=0.052). Moreover, the mean time to recovery was 6.34, 20.27, and 24.13 days in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 13.66 and 24.25 days in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (P<0.01). Conclusions: Ivermectin with doxycycline reduced the time to recovery and the percentage of patients who progress to more advanced stage of disease; in addition, Ivermectin with doxycycline reduced mortality rate in severe patients from 22.72% to 0%; however, 18.2% of critically ill patients died with Ivermectin and doxycycline therapy. Taken together, the earlier administered Ivermectin with doxycycline, the higher rate of successful therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, a study by Hashim et al. from Iraq provided insufficient details on the randomization process, had a lack of clarity on participants who were analyzed, and involved unblinded assessment of a subjective outcome [10].”
From Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179 · cited 3×
“Ivermectin reduced viral load of SARS-CoV-2 in vitro by 5000 folds within 48 h (7).”
BackgroundCoronavirus Disease 2019–COVID-19
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00028-20 · Cited by 1,876 · cited 2×
“Almost all patients start as mild-moderate disease; however, about 15% of them progress within 5-14 days post infection to a more advanced stage of the disease, being severe and critical patients [2].”
Background(2020) · Nature Communications · doi:10.1101/2020.04.14.20065771 · Cited by 1,019
Wagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D., & Jans, D. A. (2012) · Biochemical Journal · doi:10.1042/bj20120150 · Cited by 680 · cited 6×
“of several viruses such as HIV-1, Zika and dengue viruses (10).”
BackgroundMethodInfluentialSARS-CoV-2 viral load predicts COVID-19 mortality
Pujadas, E., Chaudhry, F., McBride, R., Richter, F., Zhao, S., Wajnberg, A., Nadkarni, G., Glicksberg, B. S., Houldsworth, J., & Cordon-Cardo, C. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30354-4 · Cited by 534
SARS-CoV-2 viral load predicts COVID-19 mortality
Pujadas, E., Chaudhry, F. F., McBride, R. B., et al. (2020) · medRxiv · doi:10.1101/2020.06.11.20128934 · Cited by 478 · cited 1×
“It has been found that most of COVID-19 patients who progress to severe/critical disease have high viral load of SARS-CoV-2 and over-reacting immune response (24).”
BackgroundIvermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Heidary, F., & Gharebaghi, R. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0336-z · Cited by 435 · cited 6×
“This explains how Ivermectin could alleviate symptoms of COVID-19 patients at viral replication phase (the first 7-10 days of infection) as well as the later hyperinflammatory phase [7-10].”
BackgroundInfluentialExpression of the Zinc-Finger Antiviral Protein Inhibits Alphavirus Replication
Bick, M. J., Carroll, J.-W. N., Gao, G., Goff, S. P., Rice, C. M., & MacDonald, M. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.21.11555-11562.2003 · Cited by 384 · cited 3×
“Both drugs are FDA approved and have a high historical safety record [8,10,16, 19]; moreover, no interaction is known between Ivermectin and Doxycycline or between Ivermectin-Doxycycline and any of the medications given in the standard care.”
BackgroundRajter, J. C., Sherman, M. S., Fatteh, N., Vogel, F., Sacks, J., & Rajter, J.-J. (2021) · Chest · doi:10.1016/j.chest.2020.10.009 · Cited by 318
A brief-review of the risk factors for covid-19 severity
Rod, J. E., Oviedo-Trespalacios, O., & Cortes-Ramirez, J. (2020) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2020054002481 · Cited by 232
Cited by
López-Medina, E., López, P., Hurtado, I. C., Dávalos, D. M., Ramirez, O., Martínez, E., Díazgranados, J. A., Oñate, J. M., Chavarriaga, H., Herrera, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.3071 · Cited by 376
Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001377 · Cited by 203
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
Ivermectin for preventing and treating COVID-19
Popp, M., Reis, S., Schießer, S., Hausinger, R. I., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub3 · Cited by 169
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment
Tarighi, P., Eftekhari, S., Chizari, M., Sabernavaei, M., Jafari, D., & Mirzabeigi, P. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173890 · Cited by 140
“Ivermectin group had less progression to more advanced disease and mortality rate, also significantly decreased time to recovery (Hashim et al., 2020).”
Lim, S. C. L., Hor, C. P., Tay, K. H., Jelani, A. M., Tan, W. H., Ker, H. B., Chow, T. S., Zaid, M., Cheah, W. K., Lim, H. H., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0189 · Cited by 131
Vallejos, J. A., Zoni, R., Bangher, M. D. C., Villamandos, S., Bobadilla, A., Plano, F., Campias, C., Campias, E. C., Medina, M. F., Achinelli, F., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06348-5 · Cited by 121
Antibiotics for the treatment of COVID-19
Popp, M., Stegemann, M. S., Riemer, M., Metzendorf, M., Romero, C. S., Mikołajewska, A., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015025 · Cited by 109
Padhy, B. M., Mohanty, R. R., Das, S., & Meher, B. R. (2020) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31457 · Cited by 120
Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud
Hill, A., Mirchandani, M., & Pilkington, V. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab645 · Cited by 57
Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Hill, A., Garratt, A., Levi, J., Falconer, J., Ellis, L., McCann, K., Pilkington, V., Qavi, A., Wang, J., & Wentzel, H. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab358 · Cited by 90
RetractedHariyanto, T. I., Halim, D. A., Rosalind, J., Gunawan, C., & Kurniawan, A. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2265 · Cited by 55
El-Monaem, E. M. A., Hosny, M., & Eltaweil, A. S. (2024) · Chemical Engineering and Science · doi:10.1016/j.ces.2024.119707 · Cited by 47
Misleading clinical evidence and systematic reviews on ivermectin for COVID-19
Garegnani, L., Madrid, E., & Meza, N. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2021-111678 · Cited by 95
Kirti, R., Roy, R., Pattadar, C., et al. (2021) · medRxiv · doi:10.1101/2021.01.05.21249310 · Cited by 46
Alam, S., Kamal, T. B., Sarker, M. M. R., Zhou, J., Rahman, S. M. A., & Mohamed, I. N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659577 · Cited by 55
“A recent double-blind randomized clinical trial confirmed early clinical improvement of COVID-19 patients with ivermectin and doxycycline combination compared to standard care (Hashim et al., 2020).”
BackgroundSamaha, A., Mouawia, H., Fawaz, M., Hassan, H., Salami, A., Bazzal, A., Saab, H., Al-Wakeel, M., Alsaabi, A., Chouman, M., et al. (2021) · Viruses · doi:10.3390/v13060989 · Cited by 37
RetractedKow, C. S., Merchant, H. A., Mustafa, Z. U., & Hasan, S. S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00245-z · Cited by 53
“[5] had a high risk of bias in the domain of randomization due to simple randomization method used with no information on allocation concealment and had also some concerns of bias in the domain of deviations from intervention due to unblinded participants; the trial led by Okumuş et al.”
BackgroundMethodInfluentialIvermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis
Cruciani, M., Pati, I., Masiello, F., Malena, M., Pupella, S., & Angelis, V. D. (2021) · Diagnostics · doi:10.3390/diagnostics11091645 · Cited by 36
Santin, A. D., Scheim, D. E., McCullough, P. A., Yagisawa, M., & Borody, T. J. (2021) · New Microbes and New Infections · doi:10.1016/j.nmni.2021.100924 · Cited by 41
“Combination treatments using IVM and adjuncts have shown indications of efficacy against COVID-19 in RCTs conducted to date [24,44].”
MethodZein, A. F. M. Z., Sulistiyana, C. S., Raffaello, W. M., & Pranata, R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102186 · Cited by 37
“[19] RCT 70 vs 70 200 mcg/kg OD on day 1 and 2 SOC 31.”
Izcovich, A., Peiris, S., Ragusa, M., Tortosa, F., Rada, G., Aldighieri, S., & Reveiz, L. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.12.018 · Cited by 32
“Ivermectin alone was used in most trials but five in which the intervention implemented was a combination of ivermectin with doxy-cycline [26 , 32 , 34 , 48] , or iota-Carrageenan [54] .”
Hazan, S., Davé, S., Gunaratne, A. W., Dolai, S., Clancy, R. L., McCullough, P. A., & Borody, T. J. (2022) · Future Microbiology · doi:10.2217/fmb-2022-0014 · Cited by 36
“concentration and expedite viral clearance [34].”
RetractedShafiee, A., Athar, M. M. T., Gargari, O. K., Jafarabady, K., Siahvoshi, S., & Mozhgani, S. (2022) · Virology Journal · doi:10.1186/s12985-022-01829-8 · Cited by 29
“Mortality 3472 (10 RCTs) ⨁◯◯◯ Very low [19, 24, 34, 36–39, 41, 43, 47] Progression to severe or critical state 3594 (9 RCTs) ⨁⨁◯◯ Low [19, 24, 34, 36–38, 41, 44, 47] Negative RT‐PCR 2679 (9 RCTs) ⨁◯◯◯ Very low [24, 33, 38, 41–44, 46] Recovery 1125 (4 RCTs) ⨁⨁◯◯ Low [19, 37, 38, 42] Duration of hospitalization 908 (5 R…”
Alhadrami, H. A., Sayed, A. M., Hassan, H. M., Youssif, K. A., Gaber, Y., Moatasim, Y., Kutkat, O., Mostafa, A., Ali, M. A., Rateb, M. E., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10050542 · Cited by 45
Kumar, N. D., ter Ellen, B. M., Bouma, E. M., Troost, B., van de Pol, D. P. I., van der Ende-Metselaar, H. H., van Gosliga, D., Apperloo, L., Carpaij, O. A., van den Berge, M., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01543-21 · Cited by 30
Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment
Narendrakumar, L., Joseph, I., & Thomas, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1865803 · Cited by 25
“Other clinical studies registered that utilized doxycycline therapy includes NCT04591600 and NCT04371952 [23].”
BackgroundIvermectin for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-analysis
Bryant, A., Lawrie, T. A., Dowswell, T., et al. (2021) · doi:10.21203/rs.3.rs-317485/v1 · Cited by 17
Garrido‐Mesa, J., Adams, K., Gálvez, J., & Garrido‐Mesa, N. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2054325 · Cited by 18
Bitterman, A., Martins, C. P., Cices, A. D., & Nadendla, M. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.3079 · Cited by 14
Bhowmick, S., Dang, A., Vallish, B., & Dang, S. (2021) · Drug Safety · doi:10.1007/s40264-021-01066-y · Cited by 16
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view
Shirazi, F. “., Mirzaei, R., Nakhaee, S., Nejatian, A., Ghafari, S., & Mehrpour, O. (2022) · European journal of medical research · doi:10.1186/s40001-022-00645-8 · Cited by 23
Nabi‐Afjadi, M., Mohebi, F., Zalpoor, H., Aziziyan, F., Akbari, A., Moradi‐Sardareh, H., Bahreini, E., Moeini, A. M., & Effatpanah, H. (2023) · Inflammopharmacology · doi:10.1007/s10787-022-01129-1 · Cited by 18
Scheim, D. E. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3706347 · Cited by 14
Stone, J. C., Ndarukwa, P., Scheim, D. E., Dancis, B. M., Dancis, J., Gill, M. G., & Aldous, C. M. (2022) · Biologics · doi:10.3390/biologics2030015 · Cited by 16
Murchú, É. Ó., Spillane, S., Byrne, P., O’Neill, M., Harrington, P., & Ryan, M. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211028242 · Cited by 9
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Rothrock, S. G., Weber, K. D., Giordano, P. A., & Barneck, M. D. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001461 · Cited by 14
Prospective mode of action of Ivermectin: SARS-CoV-2
Patil, V. M., Verma, S. K., & Masand, N. (2021) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2021.100018 · Cited by 17
TREATMENT MODALITIES OF THE COVID-19 PANDEMIC THROUGH REPURPOSED DRUGS AND STATUS OF VACCINES
Hussain, M. S., Mohit, M., Pamma, P., & KUMARI, B. (2021) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2021v13i2.40554 · Cited by 13
Chamie-Quintero, J. J., Hibberd, J. A., & Scheim, D. E. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3765018 · Cited by 10
Patient engagement in multimorbidity: a systematic review of patient-reported outcome measures
Barello, S., Anderson, G., Bosio, C., Lane, D. A., Leo, D. G., Lobban, T., Trevisan, C., & Graffigna, G. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1345117 · Cited by 10
Llanaj, E., & Muka, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144084 · Cited by 11
Ivermectin and the Integrity of Healthcare Evidence During COVID-19
O’Mathúna, D. P. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.788972 · Cited by 12
Can Anti-Parasitic Drugs Help Control COVID-19?
Panahi, Y., Dadkhah, M., Talei, S., Gharari, Z., Asghariazar, V., Abdolmaleki, A., Matin, S., & Molaei, S. (2022) · Future Virology · doi:10.2217/fvl-2021-0160 · Cited by 8
Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review
Asili, P., Mirahmad, M., Tabatabaei‐Malazy, O., Manayi, A., Haghighat, E., Mahdavi, M. R., & Larijani, B. A. (2021) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-021-00422-8 · Cited by 13
THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A REVIEW OF MECHANISMS AND EVIDENCE
Kalfas, S., Visvanathan, K., Chan, K., et al. (2020) · medRxiv · doi:10.1101/2020.11.30.20236570 · Cited by 8
Petersen, J. J., Kamp, C. B., Faltermeier, P., Siddiqui, F., Feinberg, J. B., Nielsen, E. E., Kristensen, A. T., Juul, S., Holgersson, J., Nielsen, N., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-064498 · Cited by 7
Manomaipiboon, A., Pholtawornkulchai, K., Poopipatpab, S., Suraamornkul, S., Maneerit, J., Ruksakul, W., Phumisantiphong, U., & Trakarnvanich, T. (2022) · Trials · doi:10.1186/s13063-022-06649-3 · Cited by 18
Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?
Golnabi, E. Y., Sanders, J. M., Johns, M. L., Lin, K., Ortwine, J. K., Wei, W., Mang, N. S., & Cutrell, J. B. (2021) · Current Infectious Disease Reports · doi:10.1007/s11908-021-00769-8 · Cited by 8
Das, L., Paik, S. P., & Sen, K. (2021) · Journal of Chemical and Engineering Data · doi:10.1021/acs.jced.1c00632 · Cited by 7
Cheng, Q., Zhao, G., Chen, J., Jia, Q., & Fang, Z. (2022) · Medicine · doi:10.1097/md.0000000000030998 · Cited by 11
Mittal, A., Elias, M., Schwartz, R., et al. (2021) · Dermatologic Therapy · doi:10.1111/dth.14984 · Cited by 6
Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19?
Ohe, M., Furuya, K., & Goudarzi, H. (2020) · BioScience Trends · doi:10.5582/bst.2020.03443 · Cited by 6
Stone, J., Ndarukwa, P., Scheim, D., et al. (2021) · doi:10.21203/rs.3.rs-1048271/v1 · Cited by 5
Evidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection
Payne, J. D., Sims, K., Peacock, C., Welch, T., & Berggren, R. (2021) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2021.1925049 · Cited by 6
“Elgazzar et al and Hashim et al reported decreased mortality with ivermectin-containing regimens.(20,21) Colchicine was recently studied by the COLOCORONA investigative group.”
BackgroundFaraj, A. M., Qadir, S. A., Mohammed, O. A., Aziz, P. Y., Alkhafaji, M., Rahman, H. S., Aziz, J. M. A., Othman, H. H., & AL-Zubaidy, A. M. A. (2022) · Iraqi Journal of Science · doi:10.24996/ijs.2022.63.3.4 · Cited by 6
“Taken together, the earlier Ivermectin in combination with doxycycline are administered, the higher rate of successful therapy [33].”
BackgroundThe Effect of Ivermectin on Reducing Viral Symptoms in Patients with Mild COVID-19
Abbas, K. U., Muhammad, S., & Ding, S. F. (2022) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.416 · Cited by 6
Kow, C. S., & Hasan, S. S. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001441 · Cited by 5
Ivermectin in the treatment of COVID-19- friend or foe?
Schellack, N., Padayachee, N., & Schellack, G. (2021) · South African General Practitioner · doi:10.36303/sagp.2021.2.1.0055 · Cited by 5
A Systematic Review and Network Meta-Analysis for COVID-19 TreatmentsPreprint
Zhang, C., Jin, H., Wen, Y., & Yin, G. (2020) · medRxiv · doi:10.1101/2020.12.21.20248621 · Cited by 2
McLindon, L. A., Ried, K., Wauchope, B. A., Murnane, L., Harradine, E., & Seman, J. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002118
“…10 – 14 and with optimized oral administration 15 and high dose safety de fi ned, 16 may have contributed to clinically signi fi cant outcomes, including faster clinical recovery and viral clearance, in some trials, 12,13 though meta-analysis of studies have not been conclusive in clinical ef fi cacy.”
Maddukuri, R. K., Desimalla, M. L., Banavathu, R., & Arepalli, S. P. K. (2025) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_117_23 · Cited by 2
“Earlier studies [9,10] that reported favorable outcomes with ivermectin included studies in which doxycycline was added to ivermectin the interventional arm [50-52] and studies that compared ivermectin with hydroxychloroquine [53,54] and lopinavir or ritonavir.”
KARALE, S. G., Bansal, V., Makadia, J., Tayyeb, M., Khan, H., Ghanta, S., Singh, R., Tekin, A., Bhurwal, A., Mutneja, H. R., et al. (2021) · medRxiv · doi:10.1101/2021.04.30.21256415 · Cited by 17
Ivermectin - an antiviral drug for the COVID-19 pandemic?
Peterson, C., Ammu, A., Mangwiro, A., & Crist, C. J. (2023) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc.v11i46.1141 · Cited by 1
Dose-Dependent Ivermectin Effect on COVID-19 Polymerase Chain Reaction Status
Sabry, N. A., Fouad, Y. M., AbdAllah, M., Cordie, A., & Esmat, G. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001490 · Cited by 1
Review of Coronavirus disease- 2019 (COVID-19) in Iraq
Al-Rawazq, H. S. A. M. (2022) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2022.10.1.0307
“[44] In the Ivermectin-Doxycycline group, 3/70 (4.”
Comprehensive review on repurposing of approved medicine in the management of COVID-19 infection
Patel, D., Shah, U., Patel, A., Patel, S. P., Patel, M. M., Patel, A. D., Patel, S., Solanki, N. D., & Pandey, N. O. (2022) · Organic Communications · doi:10.25135/acg.oc.117.2110.2244 · Cited by 3
Deng, J., Zhou, F., Heybati, K., & Kavanagh, K. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2317 · Cited by 2
Treatment of SARS-CoV-2 (COVID-19): A safety perspective
Davis, J. S., Umeh, U. S., & Saba, R. (2021) · World Journal of Pharmacology · doi:10.5497/wjp.v10.i1.1 · Cited by 1
Overview of potential drugs for the treatment of new coronavirus Infection (COVID-19)
Shirobokov, Y. E., Гладунова, Е. П., Бородулина, Е. А., & Sukhanova, A. E. (2021) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2021-6.4.7 · Cited by 1
Ciapponi, A. (2021) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v24i1.6913
FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 – A Brief ReviewPreprint
Turkia, M. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3723854
Prevalence and Risk Analysis of Human Geohelminths in Rural Communities of Ilalo, Ecuador
Galarza, F. A. P., García, G., Medina, K. E. N., & Geiger, S. M. (2026) · Parasitologia · doi:10.3390/parasitologia6010008
“…studies consistently demonstrated no significant benefit in reducing emergency consultations, hospitalizations, or mortality compared with placebo [61,62], ivermectin consumption nevertheless became generalized and may have indirectly contributed to the lower prevalence of helminth infections…”
Hazan, S., Vidal, A. C., Gkioulekas, E., Gunaratne, A. W., Dolai, S., Clancy, R. L., McCullough, P. A., & Borody, T. J. (2026) · American Journal of Infectious Diseases · doi:10.3844/ajidsp.2026.4.26
“…and doxycycline for moderately ill outpatients with baseline SpO 2 > 90% who started treatment within 3 days from the onset of symptoms (b) Hashim et al. (2021) published a very small RCT, also testing a low-dose combination therapy of ivermectin and doxycycline; however, they used…”
Kirti, R., Ranjan, A., Porel, R., Agarwal, K., Tahaseen, S. M., Shyama, S., & Kumar, A. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1163_22 · Cited by 1
“[22] It could be argued that with the very low‑case fatality rates reported with mild and moderate COVID‑19, the RCTs were insufficiently powered to detect any potential survival benefit with the drug.”
BackgroundInfluentialPérez, H. M. R., Cárdenas-Marrufo, M., Perez-Osorio, C. E., & Rivera, R. C. (2022) · International Journal of Health Science · doi:10.22533/at.ed.15923422060710
Effectiveness of Ivermectin among COVID-19 patients: A Randomized Controlled Trial
Umar, M., Shahid, R., Khan, M. M., Hayat, U., Nadar, A., & Afzal, S. (2022) · Journal of Rawalpindi Medical College · doi:10.37939/jrmc.v26i2.1802
Ivermectin Treatment for COVID-19
Ohe, M. (2021) · Ewha Medical Journal · doi:10.12771/emj.2021.44.4.146
Ivermectin Should Not Be Recommended to Treat Severe Acute Respiratory Syndrome 2 Infection
Boven, A., Kenyon, C. R., & Colebunders, R. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab456
Omrani, M. A., Salehi‐Abargouei, A., Heydari, B., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-858364/v1 · Cited by 1
"Clinical Improvement in COVID-19 After Use of Ivermectin: A Case Series"
Omololu, A. (2021) · Open Access Journal of Biomedical Science · doi:10.38125/oajbs.000298
Maxwell, D., Sanders, K., Sabot, O., et al. (2021) · medRxiv · doi:10.1101/2021.03.22.21253621
de Melo, P. M. P., & Costa, R. A. P. E. (2022) · Case Reports in Clinical Medicine · doi:10.4236/crcm.2022.115022
The Effectiveness of Ivermectin on the Risk of Mortality in COVID-19 Patients: A Meta Analysis
Pamilih, A. T., Tamtomo, D., & Murti, B. (2021) · Journal of Epidemiology and Public Health · doi:10.26911/jepublichealth.2021.06.04.02
Metadata
- Authors
- Hashim, H. A., Maulood, M. F., Rasheed, A. M., Fatak, D. F., Kabah, K. K., & Abdulamir, A. S.
- Affiliations
- Baghdad Medical City (IQ)
- Ministry of Health (IQ)
- Nahrain University (IQ)
- ORCID
- Hashim, Hashim A.
- Venue
- Iraqi journal of Medical Sciences
- Publisher
- openRxiv
- Published
- 2020-10-27
- Volume
- 19
- Issue
- 1
- ISSN
- 1681-6579 (ISSN-L)
- OpenAlex
- W4287129885
- Cited by
- 98
- References
- 26
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 25 · 2021: 51 · 2020: 9
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Iraqi journal of Medical Sciences (publishedVersion, cc-by-nc-nd)
- medRxiv (acceptedVersion, cc-by-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Keywords
- COVID-19 pandemic, ivermectin, doxycycline, drug repurposing, combination therapy, disease progression, mortality, time to recovery, severe COVID-19, critical COVID-19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.